[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR17C1031I1 - 3-((3R,4R)-4-METHYL-3-[METHYL-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-AMINO]-PIPERIDINYL)-3-OXO-PROPIONITRILE AS AN INHIBITOR OF PROTEIN KINASE - Google Patents

3-((3R,4R)-4-METHYL-3-[METHYL-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-AMINO]-PIPERIDINYL)-3-OXO-PROPIONITRILE AS AN INHIBITOR OF PROTEIN KINASE

Info

Publication number
FR17C1031I1
FR17C1031I1 FR17C1031C FR17C1031I1 FR 17C1031 I1 FR17C1031 I1 FR 17C1031I1 FR 17C1031 C FR17C1031 C FR 17C1031C FR 17C1031 I1 FR17C1031 I1 FR 17C1031I1
Authority
FR
France
Prior art keywords
methyl
propionitrile
pyrrolo
pyrimidin
piperidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR17C1031(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of FR17C1031I1 publication Critical patent/FR17C1031I1/en
Application granted granted Critical
Publication of FR17C1031I2 publication Critical patent/FR17C1031I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR17C1031C 2001-05-31 2017-09-04 3-((3R,4R)-4-METHYL-3-[METHYL-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-AMINO]-PIPERIDINYL)-3-OXO-PROPIONITRILE AS AN INHIBITOR OF PROTEIN KINASE Active FR17C1031I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29477501P 2001-05-31 2001-05-31
US34104801P 2001-12-06 2001-12-06
EP02733058A EP1392694A1 (en) 2001-05-31 2002-05-29 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo[2,3]pyrimidine derivatives as protein kinases inhibitors

Publications (2)

Publication Number Publication Date
FR17C1031I1 true FR17C1031I1 (en) 2017-10-13
FR17C1031I2 FR17C1031I2 (en) 2018-11-02

Family

ID=26968730

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1031C Active FR17C1031I2 (en) 2001-05-31 2017-09-04 3-((3R,4R)-4-METHYL-3-[METHYL-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-AMINO]-PIPERIDINYL)-3-OXO-PROPIONITRILE AS AN INHIBITOR OF PROTEIN KINASE

Country Status (52)

Country Link
US (2) US7301023B2 (en)
EP (3) EP1666481B9 (en)
JP (1) JP4381137B2 (en)
KR (5) KR100868814B1 (en)
CN (1) CN1729192A (en)
AP (1) AP1859A (en)
AR (2) AR037321A1 (en)
AT (1) ATE519741T1 (en)
AU (2) AU2002304401C1 (en)
BE (1) BE2017C032I2 (en)
BG (1) BG66489B1 (en)
BR (1) BR0209246A (en)
CA (1) CA2448281C (en)
CL (1) CL2008000762A1 (en)
CR (1) CR10177A (en)
CU (1) CU23337B7 (en)
CY (2) CY1113322T1 (en)
CZ (1) CZ304366B6 (en)
DK (1) DK1666481T3 (en)
EA (2) EA007251B1 (en)
EC (1) ECSP034865A (en)
EE (1) EE05332B1 (en)
ES (2) ES2369226T3 (en)
FR (1) FR17C1031I2 (en)
GE (1) GEP20063784B (en)
GT (2) GT200200100AA (en)
HR (1) HRP20030943B1 (en)
HU (2) HU230876B1 (en)
IL (1) IL158588A0 (en)
IS (1) IS3023B (en)
LT (1) LTC1666481I2 (en)
LU (1) LUC00031I2 (en)
MA (1) MA27029A1 (en)
MX (1) MXPA03011062A (en)
MY (1) MY129649A (en)
NL (1) NL300887I2 (en)
NO (3) NO328578B1 (en)
NZ (2) NZ530380A (en)
OA (1) OA12612A (en)
PA (1) PA8546301A1 (en)
PE (1) PE20030561A1 (en)
PL (2) PL228155B1 (en)
PT (1) PT1666481E (en)
RS (1) RS52144B (en)
SI (1) SI1666481T1 (en)
SK (2) SK288199B6 (en)
TN (1) TNSN03128A1 (en)
TW (2) TWI316061B (en)
UA (1) UA80093C2 (en)
UY (1) UY27317A1 (en)
WO (1) WO2002096909A1 (en)
ZA (1) ZA200307982B (en)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (en) 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
MXPA02005675A (en) 1999-12-10 2002-09-02 Pfizer Prod Inc PYRROLO[2,3 d]PYRIMIDINE COMPOUNDS.
EP1294724B1 (en) * 2000-06-26 2006-04-19 Pfizer Products Inc. Pyrrolo¬2,3-d|pyrimidine compounds as immunosuppressive agents
GT200200234A (en) 2001-12-06 2003-06-27 NEW CRYSTAL COMPOUNDS
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004014382A1 (en) 2002-07-29 2004-02-19 Rigel Pharmaceuticals Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
AU2003250197B2 (en) * 2002-08-27 2009-11-12 Merck Patent Gmbh Glycinamide derivatives as raf-kinase inhibitors
KR20050086784A (en) 2002-11-26 2005-08-30 화이자 프로덕츠 인크. Method of treatment of transplant rejection
RS53109B (en) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
MXPA06012663A (en) * 2004-05-03 2007-01-16 Novartis Ag Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor.
EP1768982A2 (en) 2004-06-29 2007-04-04 Amgen Inc. Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity
AR050365A1 (en) 2004-08-02 2006-10-18 Osi Pharm Inc INHIBITING COMPOUNDS OF ARIL-AMINO PIRROLOPIRIMIDINE PULROLOPIRIMIDINE REPLACED
US20090156602A1 (en) * 2004-11-24 2009-06-18 Nigel Graham Cooke Organic Compounds
AR054416A1 (en) 2004-12-22 2007-06-27 Incyte Corp PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
CN105348203B (en) 2005-06-08 2018-09-18 里格尔药品股份有限公司 Inhibit the composition and method of JAK approach
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP5071374B2 (en) 2005-07-14 2012-11-14 アステラス製薬株式会社 Heterocyclic Janus Kinase 3 Inhibitor
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
DK1913000T3 (en) 2005-07-29 2012-03-12 Pfizer Prod Inc Pyrrolo [2,3-d] pyrimidine derivatives; their intermediates and synthesis
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
ES2611588T3 (en) 2005-12-13 2017-05-09 Incyte Holdings Corporation Pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines substituted with heteroaryl as Janus kinase inhibitors
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
LT3070090T (en) 2007-06-13 2019-06-25 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
CL2008001709A1 (en) 2007-06-13 2008-11-03 Incyte Corp Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
WO2009007839A1 (en) * 2007-07-11 2009-01-15 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
CN102007124B (en) 2008-02-15 2014-06-18 里格尔制药公司 Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
MX2010011463A (en) 2008-04-16 2011-06-03 Portola Pharm Inc 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors.
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2009131687A2 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
AU2009276420A1 (en) * 2008-08-01 2010-02-04 Biocryst Pharmaceuticals, Inc. Piperidine derivatives as JAK3 inhibitors
PT2384326E (en) 2008-08-20 2014-06-09 Zoetis Llc Pyrrolo[2,3-d]pyrimidine compounds
CA2752150A1 (en) * 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
JP5709276B2 (en) 2009-04-20 2015-04-30 オースペックス ファーマシューティカルズ，エルエルシー Piperidine inhibitor of Janus kinase 3
US8604043B2 (en) 2009-05-22 2013-12-10 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
JP5658756B2 (en) * 2009-09-10 2015-01-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ JAK inhibitors
EA021478B1 (en) 2009-10-09 2015-06-30 Инсайт Корпорейшн HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
CA2776028C (en) 2009-10-15 2015-12-01 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
WO2011075334A1 (en) 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
AR079984A1 (en) * 2010-01-12 2012-03-07 Hoffmann La Roche TRICYCLIC HETEROCICLIC COMPOUNDS, COMPOSITIONS AND ITS USE IN THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF JAK1
JP2013518882A (en) 2010-02-05 2013-05-23 ファイザー・インク Pyrrolo [2,3-d] pyrimidine urea compounds as JAK inhibitors
EP4036088B1 (en) 2010-03-10 2024-04-03 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
TW201300360A (en) 2010-11-01 2013-01-01 Portola Pharm Inc Nicotinamides as JAK kinase modulators
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
BR112013012502A2 (en) 2010-11-19 2019-03-06 Incyte Corporation substituted cyclobutyl pyrrolopyridine and derivative pyrrolopyrimidine derivatives as jak inhibitors
EP2481411A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
EP2481397A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Pharmaceutical compositions comprising tasocitinib
EP2675451B9 (en) 2011-02-18 2017-07-26 Novartis Pharma AG mTOR/JAK INHIBITOR COMBINATION THERAPY
EP2691395B1 (en) 2011-03-28 2017-08-30 ratiopharm GmbH Processes for preparing tofacitinib salts
US9050342B2 (en) 2011-03-29 2015-06-09 Pfizer Inc. Beneficial effects of combination therapy on cholesterol
AU2012241018B2 (en) * 2011-04-08 2015-11-12 Pfizer Inc. Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
EP2524688B1 (en) 2011-05-11 2013-05-01 ratiopharm GmbH Composition for modified release comprising ranolazine
EP2721028B1 (en) 2011-06-20 2015-11-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
IN2014CN04065A (en) 2011-11-23 2015-09-04 Portola Pharm Inc
CA2856722C (en) * 2011-11-30 2022-11-22 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
US10821111B2 (en) 2011-11-30 2020-11-03 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP2791141B1 (en) 2011-12-15 2017-02-08 ratiopharm GmbH Tofacitinib mono-tartrate salt
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2014016338A1 (en) 2012-07-25 2014-01-30 Lek Pharmaceuticals D.D. New synthetic route for the preparation of 3-amino-piperidine compounds
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
CN113384546A (en) 2012-11-15 2021-09-14 因赛特公司 Sustained release dosage forms of ruxolitinib
CN104955803B (en) * 2012-11-30 2017-11-28 斯洛文尼亚莱柯制药股份有限公司 3 aminopiperidines are prepared by nitro tetrahydropyridine precursor
WO2014097150A1 (en) 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Process for the preparation of tofacitinib and intermediates thereof
US9670160B2 (en) 2012-12-28 2017-06-06 Glenmark Pharmaceuticals Limited Process for the preparation of tofacitinib and intermediates thereof
MY177476A (en) 2013-02-22 2020-09-16 Pfizer Pyrrolo [2,3-d]pyrimidine derivatives as inhibitors of janus kinases (jak)
AR095018A1 (en) 2013-03-06 2015-09-16 Incyte Corp PROCESSES AND INTERMEDIATES TO MAKE A JAK INHIBITOR
JP6041823B2 (en) 2013-03-16 2016-12-14 ファイザー・インク Tofacitinib oral sustained release dosage form
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
CN104513248B (en) * 2013-09-30 2019-05-24 重庆医药工业研究院有限责任公司 A kind of purification process of tropsch imatinib intermediate
AU2014358792C1 (en) 2013-12-05 2021-08-26 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
BR112015025543B1 (en) 2013-12-09 2020-11-03 Unichem Laboratories Limited process for the preparation of (3r, 4r) - (1-benzyl-4-methylpiperidine-3-yl) -methylamine and intermediate compounds
US9260438B2 (en) 2014-02-06 2016-02-16 Apotex Inc. Solid forms of tofacitinib salts
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
JP6585158B2 (en) 2014-08-12 2019-10-02 ファイザー・インク Pyrrolo [2,3-d] pyrimidine derivatives useful for the inhibition of Janus kinase
UA118149C2 (en) 2015-01-20 2018-11-26 Вуксі Фортуне Фармасьютікал Ко., Лтд Jak inhibitor
US10479763B2 (en) 2015-02-17 2019-11-19 Amorepacific Corporation Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives
CN104761556B (en) * 2015-03-21 2017-06-23 河北国龙制药有限公司 Support method replaces cloth impurity and its synthetic method, and support method for the quality control method of cloth for cloth intermediate impurities, support method
EP3078665A1 (en) * 2015-04-10 2016-10-12 OLON S.p.A. Efficient method for the preparation of tofacitinib citrate
DK3290418T3 (en) 2015-04-29 2019-07-01 Wuxi Fortune Pharmaceutical Co Ltd Janus Kinase (JAK) Inhibitors
WO2016178110A1 (en) 2015-05-01 2016-11-10 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
PL3305788T3 (en) 2015-05-29 2021-03-08 Wuxi Fortune Pharmaceutical Co., Ltd Janus kinase inhibitor
JP6507272B2 (en) * 2015-07-27 2019-04-24 ユニケム ラボラトリーズ リミテッド Tofacitinib orally disintegrating tablet
KR101771219B1 (en) * 2015-08-21 2017-09-05 양지화학 주식회사 Janus kinase 1 selective inhibitors and their pharmaceutical use
CN108472298B (en) 2015-11-24 2021-04-20 深圳阿拉丁医疗科技有限公司 Selective kinase inhibitors
CN105348287A (en) * 2015-11-30 2016-02-24 宁波立华制药有限公司 Novel synthesis process of tofacitinib citrate
KR102565407B1 (en) * 2016-01-04 2023-08-10 (주)아모레퍼시픽 Method for chiral resolution of n-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives by using polar aprotic solvent
US20190083609A1 (en) 2016-01-18 2019-03-21 Helmoltz Zentrum München - Deutsches Forschungszentrum Für Gesundheit And Umwelt (Gmbh) Tofacitinib as vaccination immune modulator
SG11201811470PA (en) 2016-06-30 2019-01-30 Daewoong Pharmaceutical Co Ltd Pyrazolopyrimidine derivatives as kinase inhibitor
CN106831538B (en) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 The preparation method of tropsch imatinib intermediate
KR102398659B1 (en) 2017-03-17 2022-05-16 주식회사 대웅제약 Pyrrolotriazine derivatives as kinase inhibitor
CN107602569A (en) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 A kind of new pyrrole simultaneously [2,3 d] pyrimidine compound and its preparation method and use
KR102078805B1 (en) 2017-11-30 2020-02-19 보령제약 주식회사 Pharmaceutical Composition Comprising Tofacitinib
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
RU2758370C1 (en) 2017-12-28 2021-10-28 Даевунг Фармасьютикал Ко., Лтд. Derivatives of oxifluoropiperidine as a kinase inhibitor
KR102577241B1 (en) 2017-12-28 2023-09-11 주식회사 대웅제약 Amino-fluoropiperidine derivatives as kinase inhibitor
KR102577242B1 (en) 2017-12-28 2023-09-11 주식회사 대웅제약 Amino-methylpiperidine derivatives as kinase inhibitor
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
JP7324210B2 (en) * 2018-01-31 2023-08-09 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド Topical preparations containing tofacitinib
HUE067471T2 (en) 2018-03-30 2024-10-28 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
KR102131107B1 (en) * 2019-01-15 2020-07-07 주식회사 다산제약 Novel method for preparing 3-amino-piperidine
CA3132109A1 (en) 2019-03-13 2020-09-17 Intas Pharmaceuticals Ltd. Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
EP3946606A1 (en) 2019-03-27 2022-02-09 Insilico Medicine IP Limited Bicyclic jak inhibitors and uses thereof
ES2977277T3 (en) * 2019-04-05 2024-08-21 Yuhan Corp Processes for preparing (3R,4R)-1-benzyl-n,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib by using the same
MX2022005882A (en) 2019-11-14 2022-06-14 Pfizer 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7- methoxyisoquinoline-6-carboxamide combinations and oral dosage forms.
US20220389010A1 (en) 2019-11-25 2022-12-08 Daewoong Pharmaceutical Co., Ltd. Novel Triazolopyridine Derivatives and Pharmaceutical Composition Comprising Same
US20230149407A1 (en) 2020-04-04 2023-05-18 Pfizer Inc. Methods of Treating Coronavirus Disease 2019
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4308568A1 (en) * 2021-03-15 2024-01-24 Chiesi Farmaceutici S.p.A. Heterocyclic derivatives as janus kinase inhibitors
EP4180042A1 (en) 2021-11-15 2023-05-17 Sanovel Ilac Sanayi Ve Ticaret A.S. A film coated tablet comprising micronized tofacitinib

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8403224A (en) 1984-10-24 1986-05-16 Oce Andeno Bv DIOXAPHOSPHORINANS, THEIR PREPARATION AND THE USE FOR SPLITTING OF OPTICALLY ACTIVE COMPOUNDS.
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE59500788D1 (en) 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidine derivatives with antiproliferative activity
JPH07330732A (en) * 1994-06-10 1995-12-19 Kyorin Pharmaceut Co Ltd Optically active 3-amino-1-benzylpiperidine derivative
US6136596A (en) * 1995-05-19 2000-10-24 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
JP3290666B2 (en) 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド Heterocyclic fused-ring pyrimidine derivatives
ES2167586T3 (en) 1995-07-05 2002-05-16 Du Pont FUNGICIDE PYRIMIDINONES.
BR9609617B1 (en) 1995-07-06 2010-07-27 7h-pyrrol [2,3-d] pyrimidine derivatives, and pharmaceutical composition.
AR004010A1 (en) 1995-10-11 1998-09-30 Glaxo Group Ltd HETERO CYCLIC COMPOUNDS
CA2209598C (en) 1995-11-14 2005-06-07 Pharmacia & Upjohn Spa Aryl and heteroaryl purine compounds
EP0888349B1 (en) 1996-01-23 2002-05-22 Novartis AG Pyrrolopyrimidines and processes for their preparation
CH690773A5 (en) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo (2,3-d) pyrimides and their use.
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU1794697A (en) 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
CA2260058A1 (en) 1996-07-13 1998-01-22 Kathryn Jane Smith Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
DE69738468T2 (en) 1996-08-23 2009-01-08 Novartis Ag SUBSTITUTED PYRROLOPYRIMIDINES AND METHOD FOR THE PRODUCTION THEREOF
CA2272705C (en) 1996-11-27 2003-03-18 Pfizer Inc. Fused bicyclic pyrimidine derivatives
ES2301194T3 (en) 1997-02-05 2008-06-16 Warner-Lambert Company Llc PIRIDO 2,3-D PYRIMIDINS AND 4-AMINOPIRIMIDINAS AS INHIBITORS OF THE CELL PROLIFERATION.
WO1998043087A1 (en) 1997-03-24 1998-10-01 Pharmacia & Upjohn Company Method for identifying inhibitors of jak2/cytokine receptor binding
WO1999051599A1 (en) 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors
EP1082311A1 (en) 1998-05-28 2001-03-14 Parker Hughes Institute Quinazolines for treating brain tumor
AU3951899A (en) * 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
PA8474101A1 (en) * 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
JP2004504259A (en) 1998-06-30 2004-02-12 パーカー　ヒューズ　インスティテュート Method of inhibiting C-JUN expression using JAK-3 inhibitor
KR20010089171A (en) 1998-08-21 2001-09-29 추후제출 Quinazoline derivatives
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
MXPA02005675A (en) * 1999-12-10 2002-09-02 Pfizer Prod Inc PYRROLO[2,3 d]PYRIMIDINE COMPOUNDS.
EP1294724B1 (en) 2000-06-26 2006-04-19 Pfizer Products Inc. Pyrrolo¬2,3-d|pyrimidine compounds as immunosuppressive agents
GT200200234A (en) * 2001-12-06 2003-06-27 NEW CRYSTAL COMPOUNDS
EP1768982A2 (en) * 2004-06-29 2007-04-04 Amgen Inc. Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity

Also Published As

Publication number Publication date
UY27317A1 (en) 2003-02-28
ZA200307982B (en) 2004-10-14
PT1666481E (en) 2012-12-03
RS52144B (en) 2012-08-31
IS3023B (en) 2020-08-15
JP2004534047A (en) 2004-11-11
US20040229923A1 (en) 2004-11-18
AP1859A (en) 2008-07-02
OA12612A (en) 2006-06-09
EP1666481A3 (en) 2006-11-29
NO20035201D0 (en) 2003-11-24
KR20080002931A (en) 2008-01-04
BG108389A (en) 2005-01-31
AU2008203170B2 (en) 2009-06-18
HUP0400152A2 (en) 2007-07-30
EA200600575A1 (en) 2006-08-25
KR20060133117A (en) 2006-12-22
HU230876B1 (en) 2018-11-29
HRP20030943B1 (en) 2011-11-30
MY129649A (en) 2007-04-30
GT200200100A (en) 2003-02-11
CL2008000762A1 (en) 2008-07-04
PL367945A1 (en) 2005-03-07
CN1729192A (en) 2006-02-01
LUC00031I2 (en) 2017-10-11
WO2002096909A1 (en) 2002-12-05
CY2017028I1 (en) 2018-02-14
SK14652003A3 (en) 2004-05-04
HRP20030943A2 (en) 2005-08-31
TW200413370A (en) 2004-08-01
TWI316061B (en) 2009-10-21
ECSP034865A (en) 2004-01-28
DK1666481T3 (en) 2012-10-15
EP1666481B9 (en) 2013-05-01
SK288199B6 (en) 2014-06-03
ATE519741T1 (en) 2011-08-15
PA8546301A1 (en) 2003-05-14
US7432370B2 (en) 2008-10-07
CY1113322T1 (en) 2016-06-22
LTPA2017025I1 (en) 2017-09-11
EE05332B1 (en) 2010-08-16
IS6993A (en) 2003-10-13
TWI310384B (en) 2009-06-01
CU23337B7 (en) 2009-01-20
LUC00031I1 (en) 2017-08-10
EA007251B1 (en) 2006-08-25
SK288192B6 (en) 2014-06-03
NZ540332A (en) 2007-05-31
NO328578B1 (en) 2010-03-22
EA012666B1 (en) 2009-12-30
EP1609781A1 (en) 2005-12-28
ES2369226T3 (en) 2011-11-28
JP4381137B2 (en) 2009-12-09
NO20093135L (en) 2003-11-24
NL300887I2 (en) 2017-08-31
UA80093C2 (en) 2007-08-27
BE2017C032I2 (en) 2021-07-19
EP1609781B1 (en) 2011-08-10
LTC1666481I2 (en) 2018-06-25
KR20060014459A (en) 2006-02-15
EP1392694A1 (en) 2004-03-03
CA2448281C (en) 2009-05-05
CA2448281A1 (en) 2002-12-05
KR20040003037A (en) 2004-01-07
BG66489B1 (en) 2015-05-29
KR20080083028A (en) 2008-09-12
BR0209246A (en) 2004-06-15
HUS1900008I1 (en) 2020-02-28
PE20030561A1 (en) 2003-06-23
NZ530380A (en) 2005-08-26
NO20035201L (en) 2003-11-24
TNSN03128A1 (en) 2005-12-23
KR100868814B1 (en) 2008-11-14
NO2017047I1 (en) 2017-09-08
US7301023B2 (en) 2007-11-27
CR10177A (en) 2008-08-19
KR100869409B1 (en) 2008-11-21
EE200300594A (en) 2004-04-15
AU2002304401C1 (en) 2009-03-05
AP2002002550A0 (en) 2002-06-30
AR045680A2 (en) 2005-11-09
AU2002304401B2 (en) 2008-04-17
GEP20063784B (en) 2006-04-10
SI1666481T1 (en) 2012-11-30
US20030073719A1 (en) 2003-04-17
AU2008203170A1 (en) 2008-08-07
EP1666481B1 (en) 2012-09-19
MXPA03011062A (en) 2004-03-19
HUP0400152A3 (en) 2012-12-28
EP1666481A2 (en) 2006-06-07
MA27029A1 (en) 2004-12-20
PL409305A1 (en) 2014-12-22
CY2017028I2 (en) 2018-02-14
PL228155B1 (en) 2018-02-28
CZ20033260A3 (en) 2004-03-17
FR17C1031I2 (en) 2018-11-02
IL158588A0 (en) 2004-05-12
AR037321A1 (en) 2004-11-03
CZ304366B6 (en) 2014-04-02
GT200200100AA (en) 2007-07-06
KR100926875B1 (en) 2009-11-16
EA200301193A1 (en) 2004-04-29
ES2393385T3 (en) 2012-12-20
YU92303A (en) 2006-08-17

Similar Documents

Publication Publication Date Title
FR17C1031I2 (en) 3-((3R,4R)-4-METHYL-3-[METHYL-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-AMINO]-PIPERIDINYL)-3-OXO-PROPIONITRILE AS AN INHIBITOR OF PROTEIN KINASE
CA2469350A1 (en) 3-{4-methyl-3[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt
HUP0400300A3 (en) Pyrrolopyrimidines as protein kinase inhibitors
NO20041887L (en) Benzomidazoles useful as protein kinase inhibitors
PT1235830E (en) PYRIMIDINE-2,3-D | PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS
AU2002310187A1 (en) Inhibitors of protein kinase for the treatment of disease
EE200200506A (en) 5-alkylpyrido [2,3-d] pyrimidines as tyrosine kinase inhibitors
WO2007012953A3 (en) Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
AU2003254053A1 (en) Pyrazolopyrimidines as protein kinase inhibitors
AU2002357193A1 (en) Thienopyrimidine compounds as protein tyrosine kinase inhibitors
CY2008015I2 (en) BICYCLIC ETEOAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
NO20011575D0 (en) Substituted 3-cyanoquinolines as protein tyrosine kinase inhibitors
NO20035728D0 (en) Pyrrolopyrimidines as protein kinase inhibitors
HK1080074A1 (en) 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
GB0213809D0 (en) Dynamic shaping of laser beams
AU2002220630A1 (en) Regulation of human serine-threonine protein kinase
ITMI20010667A0 (en) COMPOSITION OF ODOR ABSORBERS PARTICULARLY FOR REFRIGERATORS
AU2002251636A1 (en) Novel use of tyrosine kinase inhibitor
IL145329A0 (en) Protein tyrosine kinase inhibitors
AU2002307861A1 (en) Imidazole-2-carboxamide derivatives as raf kinase inhibitors
AU2002348010A1 (en) Novel germinal center kinase proteins, compositions, and methods of use